mulberry black handbag Bracco Imaging reinforces its portfolio in Interventional Oncolo
Information contained on this page is provided by an independent third party content provider. Frankly and this Site make no warranties or representations in connection therewith. an Italian company focused on Augmented Reality Guidance technology in Interventional Oncology procedures to expand its portfolio of solutions for Interventional Oncology.
One of the key challenges clinicians have to face during interventional procedures is the precise introduction of a probe into a deep target within the body that is not visible. Clinical efforts in this field have been concentrated toward developing higher resolution images, better navigation and image fusion tools. developed Endosight a high end guidance system based on augmented reality and a sophisticated imaging software (Ablation fit) for 3D reconstruction, planning and diagnosis to be used in surgery during mini invasive Percutaneous Tumor Ablation procedures in Computed Tomography based Interventional Oncology. The solution has been developed to provide intuitive visualization with no need for manipulation or further interaction to ensure accurate targeting, without compromising workflow, procedure duration, or interventional outcomes. “In preclinical studies, Endosight demonstrated unparalleled performances that make it possible to “see through” the patient without the need for direct imaging support, thanks to the augmented reality. I have been developing imaging innovations for more than 30 years, and I consider Bracco innovative culture the best environment to make new methods grow and spread.”
“We delighted about this partnership as it will unleash new opportunities to address unmet medical needs in the field of Interventional Oncology,” said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “This partnership is the beginning of an unedited integration of imaging, guidance and treatment. The innovations behind Endosight and Ablation fit are paradigmatic, and new developments are going to further complete the portfolio. We are first movers, and we want to keep this advantage with such strategic cooperation. Our vision is to make high end innovation and to keep the user experience simple.”
“Bracco journey focuses on the exploitation of new image guided solutions for diagnosis and treatment of oncological diseases via internal developments and alliances,” said Micol Fornaroli, Chief Strategy Officer at Bracco Imaging. is an important step along this pathway as it will give the interventional oncologists top tier, highly innovative tools to plan, verify and manage patients undergoing interventional oncology procedures,” she concluded.
Ablation fit will be initially distributed in Europe by Bracco Imaging through its commercial network. With an on going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe and Japan operating through the Joint Venture Bracco Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.
Operational investments have been made in order to achieve top quality and compliances with a sustainable eco friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.
Bracco Imaging is an innovative Research and Development (R player with an efficient process oriented approach and a track record of innovation in the diagnostic imaging industry. R activities are managed in the three Research Centres located in Italy, Switzerland, and the USA.